[en] Background: Two-dose varicella vaccination is recommended for optimal control of varicella in populations with high (>90%) 1-dose coverage. Optimal timing of the second dose may depend on whether breakthrough varicella results from primary vaccine failure (no protective immunity after vaccination) or secondary vaccine failure (waning protective immunity).
Methods: Published literature (1995 to 2012) on vaccine failure after varicella vaccination cited in PubMed and other online sources was reviewed.
Results: Nineteen publications detailed 21 varicella outbreaks with breakthrough varicella rates ranging from 0% to 42%; the publications showed no consistent trend between breakthrough varicella rate and time since vaccination.
Conclusions: Literature to date indicates a relatively high rate of primary vaccine failure and limited evidence of secondary vaccine failure among 1-dose varicella vaccine recipients, suggesting that a short interval between 2 doses might be preferable in countries considering implementation of universal varicella vaccination to reduce breakthrough varicella. However, any potential disruption to well-established vaccination schedules should be considered.
Disciplines :
Immunology & infectious disease
Author, co-author :
Bonanni, Paolo; University of Florence > Department of Public Health
Gershon, Anne; Columbia University College of Physicians and Surgeons > Department of Pediatrics
Gershon, Michael; Columbia University College of Physicians and Surgeons > Department of Pathology and Cell Biology
Kulcsár, Andrea; Szent László Hospital (Budapest) > Ward for Pediatric Infectious Diseases
Papaevangelou, Vassiliki; University of Athens Medical School > Second Department of Pediatrics
Rentier, Bernard ; Université de Liège - ULiège > Services administratifs généraux > Recteur
Sadzot-Delvaux, Catherine ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Virologie et immunologie
Usonis, Vytautas; Vilnius University. Faculty of Medicine > Clinic of Paediatrics
Vesikari, Timo; University of Tampere Medical School > Vaccine Research Center
Weil-Olivier, Catherine; University of Paris VII > Department of General Pediatrics
de Winter, Peter; Spaarne Hospital (Hoofddorp, The Netherlands) > Department of Pediatrics
Wutzler, Peter; Jena University Hospital Friedrich-Schiller University > Institute of Virology and Antiviral Therapy
Language :
English
Title :
Primary Versus Secondary Failure After Varicella Vaccination: Implications for Interval Between 2 Doses
Publication date :
2013
Journal title :
Pediatric Infectious Disease Journal
ISSN :
0891-3668
eISSN :
1532-0987
Publisher :
Williams and Wilkins, Baltimore, United States - Maryland
Volume :
32
Issue :
7
Pages :
305-313
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
GlaxoSmithKline Biologicals SA (GSK)
Commentary :
All authors are members of the Working Against Varicella in Europe group
Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458
Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611
Shah SS, Wood SM, Luan X, et al. Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J. 2010;29:199-204
Siedler A, Arndt U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill. 2010;15:19530
Giammanco G, Ciriminna S, Barberi I, et al. Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years. Euro Surveill. 2009;14:19321
Spackova M, Muehlen M, Siedler A. Complications of varicella after implementation of routine childhood varicella vaccination in Germany. Pediatr Infect Dis J. 2010;29:884-886
Quian J, Rüttimann R, Romero C, et al. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005. Arch Dis Child. 2008;93:845-850
Pozza F, Piovesan C, Russo F, et al. Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine. 2011;29:9480-9487
Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(suppl 2):S82-S89
Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356:1121-1129
Gershon AA, Katz SL. Perspective on live varicella vaccine. J Infect Dis. 2008;197(suppl 2):S242-S245
Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. 2011;203:312-315
Arnedo-Pena A, Puig-Barberà J, Aznar-Orenga MA, et al. Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain. Pediatr Infect Dis J. 2006;25:774-778
Bayer O, Heininger U, Heiligensetzer C, et al. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007;25:6655-6660
Buchholz U, Moolenaar R, Peterson C, et al. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics. 1999;104(3 Pt 1):561-563
Centers for Disease Control and Prevention. Outbreak of varicella among vaccinated children-Michigan, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:389-392
Centers for Disease Control and Prevention. Varicella outbreak among vaccinated children-Nebraska, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:749-752
Dworkin MS, Jennings CE, Roth-Thomas J, et al. An Outbreak of Varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002;35:102-104
Galil K, Fair E, Mountcastle N, et al. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002;186:102-105
Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-1915
Gould PL, Leung J, Scott C, et al. An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients-Arkansas, 2006. Pediatr Infect Dis J. 2009;28:678-681
Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005;115:1488-1493
Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997;278:1495-1499
Lai CC, Chen SC, Jiang DD. An outbreak of varicella among schoolchildren in Taipei. BMC Public Health. 2011;11:226
Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis. 2004;190:477-483
Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117:e1070-e1077
Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics. 2005;115:900-905
Miron D, Lavi I, Kitov R, et al. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J. 2005;24:233-236
Parker AA, Reynolds MA, Leung J, et al. Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement-Maine, 2006. J Infect Dis. 2008;197(suppl 2):S101-S107
Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine. 2010;28:686-691
Tafuri S, Martinelli D, De Palma M, et al. Report of varicella outbreak in a low vaccination coverage group of otherwise healthy children in Italy: the role of breakthrough and the need of a second dose of vaccine. Vaccine. 2010;28:1594-1597
Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004;113(3 Pt 1):455-459
Centers for Disease Control and Prevention. Public health response to varicella outbreaks-United States, 2003-2004. MMWR Morb Mortal Wkly Rep. 2006;55:993-995
Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-855
Vázquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-960
Passwell JH, Hemo B, Levi Y, et al. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J. 2004;23:221-226
Sheffer R, Segal D, Rahamani S, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434-437
Huang WC, Huang LM, Chang IS, et al. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine. 2011;29:2756-2760
Hirose M, Hidaka Y, Miyazaki C, et al. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. Scand J Infect Dis. 1997;29:187-190
Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174(suppl 3):S330-S334
Black S, Ray P, Shinefield H, et al. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis. 2008;197(suppl 2):S139-S142
Verstraeten T, Jumaan AO, Mullooly JP, et al.Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003;112:e98-103
Lee LE, Ho H, Lorber E, et al. Vaccine-era varicella epidemiology and vaccine effectiveness in a public elementary school population, 2002-2007. Pediatrics. 2008;121:e1548-e1554
Kurugol Z, Halicioglu O, Koc F, et al. Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey. Int J Infect Dis. 2011;15:e475-e480
Barzaga NG, Florese RH, Bock HL. Reactogenicity and immunogenicity of a varicella vaccine in healthy seronegative and seropositive subjects. Southeast Asian J Trop Med Public Health. 2002;33:259-267
Clements DA, Armstrong CB, Ursano AM, et al. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J. 1995;14:874-879
Gatchalian S, Tabora C, Bermal N, et al. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. Am J Trop Med Hyg. 2004;70:273-277
Gillet Y, Habermehl P, Thomas S, et al. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 2009;7:16
Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27:446-453
Johnson CE, Stancin T, Fattlar D, et al. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 1997;100:761-766
Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int. 2000;42:674-677
Kim SH, Lee HJ, Park SE, et al. Seroprevalence rate after one dose of varicella vaccine in infants. J Infect. 2010;61:66-72
Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002;21:337-342
Lim YJ, Chew FT, Tan AY, et al. Risk factors for breakthrough varicella in healthy children. Arch Dis Child. 1998;79:478-480
Merck. Package circular for VARIVAX™ (Varicella Virus Vaccine Live) 2001. Available at: http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Accessed January 12, 2013
Meurice F, De Bouver JL, Vandevoorde D, et al. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis. 1996;174(suppl 3):S324-S329
Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008;197:944-949
Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996;15:49-54
Nolan T, Bernstein DI, Block SL, et al.LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008;121:508-516
Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002;21:281-289
Ramkissoon A, Coovadia HM, Jugnundan P, et al. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. S Afr Med J. 1995;85:1295-1298
Rümke HC, Loch HP, Hoppenbrouwers K, et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine. 2011;29:3842-3849
Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27:724-730
Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665-669
Shinefield H, Black S, Williams WR, et al.Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:670-675
Shinefield HR, Black SB, Staehle BO, et al.Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002;21:555-561
Silber JL, Chan IS, Wang WW, et al. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Pediatr Infect Dis J. 2007;26:572-576
Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol. 2002;20:113-120
Tan AY, Connett CJ, Connett GJ, et al. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. Eur J Pediatr. 1996;155:706-711
Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139:297-304
Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995;172:217-219
Watson BM, Laufer DS, Kuter BJ, et al. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis. 1996;173:731-734
Ampofo K, Saiman L, LaRussa P, et al. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis. 2002;34:774-779
Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2001;22:279-283
Arvin A, Gershon A. Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J. 2006;25:475-476
Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20:316-319
Ludwig B, Kraus FB, Allwinn R, et al. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination. Infection. 2006;34:222-226
Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin. 2008;4:316-319
Fu C, Wang M, Liang J, et al. The effectiveness of varicella vaccine in China. Pediatr Infect Dis J. 2010;29:690-693
Tseng HF, Tan HF, Chang CK. Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan. Am J Infect Control. 2003;31:151-156
Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine. 2000;18:2375-2380
Takayama N, Minamitani M, Takayama M. High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn. 1997;39:663-668
Brisson M, Edmunds WJ, Gay NJ, et al. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine. 2000;18:2775-2778
White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992;11:19-23
Kosuwon P, Sutra S, Kosalaraksa P. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults. Southeast Asian J Trop Med Public Health. 2004;35:697-701
Czajka H, Schuster V, Zepp F, et al. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009;27:6504-6511
Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007;35:326-333
Halperin SA, Ferrera G, Scheifele D, et al. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine. 2009;27:2701-2706
Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12-18
Kuter B, Matthews H, Shinefield H, et al.Study Group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137
Reisinger KS, Brown ML, Xu J, et al.Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006;117:265-272
Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007;26:153-158
Wutzler P, Knuf M, Liese J. Varicella: efficacy of two-dose vaccination in childhood. Dtsch Arztebl Int. 2008;105:567-572
Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine. 1995;13:967-972
Wiese-Posselt M, Hellenbrand W. Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation. Euro Surveill. 2010;15:19548
Marin M, Broder KR, Temte JL, et al.Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12
Marin M, Güris D, Chaves SS, et al.Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40
Nguyen MD, Perella D, Watson B, et al. Incremental effectiveness of second dose varicella vaccination for outbreak control at an elementary school in Philadelphia, pennsylvania, 2006. Pediatr Infect Dis J. 2010;29:685-689
Gershon AA. Varicella vaccine-are two doses better than one? N Engl J Med. 2002;347:1962-1963
